---
# System prepended metadata

title: Hematopoietic Stem Cell Transplantation Market
tags: ['Hematopoietic Stem Cell Transplantation Market Size, Hematopoietic Stem Cell Transplantation Market Future, Hematopoietic Stem Cell Transplantation Market Growth']

---

Hematopoietic Stem Cell Transplantation Market Growth: Emerging Trends

![Hematopoietic Stem Cell Transplantation (HSCT) Market](https://hackmd.io/_uploads/BJ7I1Khha.jpg)

The Hematopoietic stem cell transplantation (HSCT) market involves a procedure where healthy stem cells are collected from circulating blood or bone marrow of a healthy donor and transplanted into a patient after intensive chemotherapy or radiation treatment. HSCT is an effective treatment procedure for various hematological malignancies and disorders including leukemia, lymphoma, plasma cell disorders like multiple myeloma, and genetic disorders like thalassemia, sickle cell anemia, and several others. It replaces unhealthy blood-forming cells with healthy ones. Several advances in the field of stem cell therapies, better supportive care, and growing awareness among patients about this treatment procedure have significantly contributed to the demand for HSCT.

The Global Hematopoietic stem cell transplantation (HSCT) Market is estimated to be valued at US$ 2.88 Bn in 2024 and is expected to exhibit a CAGR of 11. % over the forecast period 2023 to 2030.

Get more insights on this topic: https://www.coherentmarketinsights.com/market-insight/hematopoietic-stem-cell-transplantation-market-1250

Key Takeaways
Key players operating in the Hematopoietic stem cell transplantation (HSCT) are Pluristem Therapeutics Inc., CellGenix GmbH, Regen Biopharma Inc., Lonza Group, Kiadis Pharma, Taiga Biotechnologies, Inc., Takeda Pharmaceutical Company Limited, Escape Therapeutics, Inc., Bluebird Bio, Inc., Talaris Therapeutics, Inc., Marker Therapeutics Inc., Stempeutics Research Pvt Ltd., CBR Systems Inc., Priothera Ltd., Eurobio Scientific Group, Otsuka America Pharmaceutical, Inc., Pfizer Inc., Sanofi, FUJIFILM Holdings Corporation. The key players are working on developing new therapies, advanced techniques, and effective stem cell collection and processing methods.

The global HSCT market is primarily driven by the increasing prevalence of hematological malignancies and genetic disorders. As per WHO estimates, over 18 million new cancer cases and 9.6 million cancer deaths were reported in 2018 and the numbers are expected to rise significantly in coming years. This growing incidence of cancer is anticipated to boost the demand for HSCT procedures.

Advancements in stem cell biology and transplantation techniques have widened the scope of HSCT and reduced transplant-related risks and complications. Developments such as use of reduced intensity conditioning regimens, advanced cell processing methods, and improved supportive care practices have made HSCT a viable treatment option for older patients and those with co-morbid conditions. This has augmented the application of HSCT in clinical practice.

Market Trends
Cord blood is gaining increased acceptance as an alternative stem cell source - Umbilical cord blood is being increasingly used as an alternative stem cell source for HSCT. It has several advantages over bone marrow including easy availability, reduced risk of transmitting infections, and a lower chance of triggering graft-versus-host disease.

Private cord blood banking is on rise - Considering the potential therapeutic benefits, more parents are opting for private cord blood banking. This trend is anticipated to boost the supply of matched cord blood units in future.

Market Opportunities
Development of novel stem cell-based products - Several companies are developing new stem cell-based products including gene-edited stem cells with enhanced therapeutic properties using CRISPR/Cas9 technology. This represents a significant growth opportunity.

Expanding applications of HSCT - With ongoing research evaluating the role of HSCT in autoimmune disorders like multiple sclerosis and advancement in transplant protocol, the scope of HSCT is widening. This opens up potential new avenues of growth over the forecast period.

Impact of COVID-19 on Hematopoietic Stem Cell Transplantation Market Growth

The COVID-19 pandemic has significantly impacted the growth of the hematopoietic stem cell transplantation market. During the initial stages of the pandemic in 2020, elective procedures and non-emergency visits were postponed to focus resources on COVID-19 patients. This resulted in a decline in the number of HSCT procedures performed globally. Furthermore, travel restrictions and lockdowns made it difficult to transport stem cells and patients. The supply chain and logistics were disrupted.

However, as the healthcare systems adapted to the new normal, the market is recovering. In 2021, the number of HSCT procedures increased compared to 2020 levels. Telehealth and virtual consultations helped maintain continuity of care for existing patients. The demand for unrelated donor stem cells also increased to treat hematological cancers. Stringent safety protocols were implemented at transplant centers to minimize infection risks for immunocompromised patients. Cell and gene therapy companies continued research and clinical trials for new HSCT applications.

Looking ahead, the market is expected to grow steadily. More day-care centers are offering HSCT to reduce length of hospital stay. Public-private partnerships are working to expand unrelated donor registries. New drugs to improve transplant outcomes and reduce complications will drive market revenue. Personalized medicine approaches using stem cells offer hope in conditions like diabetes and heart disease. While short term disruptions occurred, COVID-19 has highlighted the importance of HSCT in cancer care, and long term growth remains positive.

Geographical Regions with Highest Hematopoietic Stem Cell Transplantation Market Value

North America represents the largest regional market for HSCT in terms of value, estimated at over US$ 1 billion in 2024. This is attributed to the rising incidence of blood cancers in the US and Canada, growing elderly population vulnerable to hematological malignancies, widespread health insurance coverage, and presence of leading transplant centers. Reimbursement policies favor the adoption of novel cell and gene therapies. Large pharmaceutical companies are also based in the region driving innovative research.

Asia Pacific is emerging as the fastest growing regional market for HSCT. Countries like China, India, Japan, and South Korea are investing heavily in healthcare infrastructure development. There is a growing middle class population able to afford expensive transplant procedures. Favorable regulatory guidelines encourage clinical trials. In addition, Asia Pacific hosts a very large population base and witnessed the highest increase in the number of HSCT procedures globally between 2017 to 2020. This makes it an attractive market for long term investments.

Fastest Growing Regional Market for Hematopoietic Stem Cell Transplantation

The Asia Pacific region has emerged as the fastest growing regional market for Hematopoietic Stem Cell Transplantation (HSCT) Market globally over the past five years. Countries like China, India, South Korea and Japan are witnessing rapid economic development which is positively impacting the healthcare industry. Government initiatives aim to make HSCT services more accessible. For example, the China HSCT Registry recorded over 15,000 procedures in 2021, a significant increase from previous years. Shortages in matched unrelated donors in Asia are also driving private banks and public cord blood programs. Additionally, a large patient population, rising healthcare expenditures, and improving standards of care translate to higher graft volumes in Asia compared to other regions. With continued investments, Asia Pacific is likely to account for over 30% of global HSCT market share by 2030.